Friday, July 31, 2026

North Korea Launches Ballistic Missiles: What You Need to Know About the Latest Threats

South Korea's National Security Office held an emergency meeting after North Korea launched ballistic missiles, assessing military readiness.

Against the Odds, North Korea Logs Strongest Growth in Nearly a Decade

North Korea's economy grew by 3.7% in 2023, driven by construction, mining, and manufacturing, despite declines in agriculture and trade.

Pyongyang Accuses U.S. of Turning South Korea Into Forward Base for Containing China

North Korea criticizes ROK-U.S. alliance, highlighting U.S. military strategies aimed at deterring China and raising regional tensions.

Tag: SK Bioscience

North KoreaKoreaKimMilitaryAISouth KoreamarketrelationsInternational

SK Bioscience Achieves WHO PQ Certification: What This Means for Global Vaccine Supply

SK Bioscience completed WHO's triennial review for its vaccines, enhancing international trust in its quality and operational systems.

WHO Warns of Next Pandemic as Infectious Disease Preparedness Remains Critical; SK Bioscience Draws Attention

SK Bioscience enhances South Korea's pandemic preparedness with vaccine innovations and global partnerships, focusing on future growth.

SK Bioscience Licenses CDC Rotavirus Vaccine Candidate, Expands Global Vaccine Pipeline

SK Bioscience partners with the CDC to develop a rotavirus vaccine, aiming to enhance global health and expand its vaccine portfolio.

SK Bioscience Opens Songdo Headquarters to Families as It Expands Employee-Centered Corporate Culture

SK Bioscience hosted a family open house at its new headquarters, showcasing its vision and engaging activities for employees' families.

SK Bioscience Builds Latin American Growth Momentum With Local Vaccine Manufacturing Collaboration in Colombia

SK bioscience accelerates its expansion into the Latin American market with its self-developed vaccine.

SK Bioscience Pours 4 Billion KRW into RSM01, Accelerating RSV Antibody Trials

SK Bioscience secures funding from the Light Foundation to support clinical trials for its RSV prevention monoclonal antibody RSM01.

Why Ebola Now? SK Bioscience Joins a $30 Million Global Push to Rethink Ebola Vaccine Production

SK Bioscience secures funding to enhance Ebola vaccine production, improving yield and stability for better accessibility amid outbreaks.

How SK Bioscience Plans to Dominate the Global Vaccine Market in 2026

SK Bioscience enhances its operational system with new COO and key appointments to boost global competitiveness and vaccine development.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.